| FEATURED SNIPPET TARGET (40-60 words, keep as first paragraph after H1) The best tirzepatide alternatives for weight loss include injectable semaglutide (Wegovy), oral semaglutide (the Wegovy pill, now available in US pharmacies), phentermine/topiramate (Qsymia), bupropion/naltrexone (Contrave), metformin, compounded GLP-1 medications, and medically supervised weight loss programs. Each option works through different mechanisms, with GLP-1 receptor agonists like semaglutide producing the strongest results closest to tirzepatide. |
Tirzepatide has changed what is possible in medical weight loss, with clinical trials showing average weight loss of up to 26% of body weight. But not everyone can access it. Insurance denials, supply issues, medication costs, and certain health conditions, including personal or family history of thyroid cancer, pancreatitis, or severe GI conditions, may put tirzepatide out of reach.
Fortunately, there are several proven options. For Texas patients, InjectCo clinics across the DFW metroplex, Plano, Fort Worth, Austin, The Woodlands, and Colleyville offer physician-supervised GLP-1 programs including semaglutide, tirzepatide, and compounded alternatives.
Book a free virtual consultation to find the right fit for your goals.
| 1. Semaglutide (Wegovy injectable) | Closest GLP-1 alternative to tirzepatide | |
| Mechanism | GLP-1 receptor agonist |
| FDA Status | Approved (Wegovy for obesity, Ozempic for T2D) |
| KD / Vol | Primary: tirzepatide alternative | Volume: 1,076 impressions/month (GSC) |
| Average weight loss: 10-15% of body weight with consistent useForm: once-weekly subcutaneous injectionHow it works: GLP-1 receptor agonist that slows gastric emptying, reduces appetite, and improves blood sugar regulationBest for: adults with obesity or overweight seeking a well-studied, once-weekly GLP-1 treatment with strong clinical trial dataAvailable at InjectCo: yes, with physician-guided dosing and flexible titration support | |
| 2. Oral Wegovy Pill (Semaglutide tablet 25 mg) | LIVE since January 2026 — first FDA-approved oral GLP-1 for obesity | |
| Mechanism | GLP-1 receptor agonist (oral) |
| FDA Status | Approved December 22, 2025 — now widely available |
| Why it matters | No other oral GLP-1 with this level of weight loss data existed before this approval |
| Average weight loss: ~14-17% in OASIS 4 Phase 3 trial (64 weeks)Form: once-daily oral tablet — no injections, no refrigeration requiredHow it works: same semaglutide molecule as injectable Wegovy, delivered orally at 25 mg daily with dose escalation starting at 1.5 mgBest for: patients who prefer pills over injections, those with needle anxiety, or anyone who could not tolerate injectable GLP-1sPricing: starting at $149/month self-pay for the 1.5 mg starting dose; available at CVS, Costco, and 70,000+ US pharmacies as of January 5, 2026Important note: take 30 minutes before eating with a small amount of water; do not crush or chew | |
| 3. Retatrutide (Triple Agonist GLP-1 + GIP + Glucagon) | The next-generation drug to watch | |
| Mechanism | Triple hormone receptor agonist: GLP-1 + GIP + glucagon |
| FDA Status | NOT YET APPROVED as of June 2026. Phase 3 TRIUMPH program ongoing. NDA expected late 2026 / Q1 2027. Possible approval 2027-2028. |
| Why include it here?Phase 3 TRIUMPH-1 data (May 2026): -28.3% weight loss at 80 weeks in adults with obesity. TRIUMPH-4 (Dec 2025): -28.7%. These are the highest weight loss figures ever reported in an obesity drug trial.It targets three hormone pathways vs. tirzepatide’s two (GLP-1 + GIP), potentially making it more effective than any current alternative.Eli Lilly has not yet filed an NDA. Not available by prescription or at pharmacies. Do not use compounded retatrutide without medical supervision.Patients in Texas may be eligible for TRIUMPH trial enrollment. Ask your InjectCo provider for referral information.When approved, retatrutide will likely become the strongest FDA-approved alternative to tirzepatide available. | |
| 4. Phentermine / Topiramate (Qsymia) | Fastest oral option for short-term weight reduction | |
| Mechanism | CNS stimulation + satiety enhancement |
| FDA Status | Approved for chronic weight management |
| Caution | Not for long-term use in most patients; cardiovascular contraindications |
| Average weight loss: 8-10% of body weightForm: once-daily oral capsule (appetite suppressant + metabolism enhancer)How it works: phentermine stimulates the central nervous system to reduce appetite; topiramate increases satiety and reduces calorie intakeBest for: adults needing faster near-term weight reduction who prefer oral medication and do not have cardiovascular diseaseConsiderations: not recommended for patients with heart disease, history of stroke, hyperthyroidism, or glaucoma; requires pregnancy prevention in women of childbearing ageNote: this is not a GLP-1 medication and does not carry the same long-term metabolic benefits as semaglutide or tirzepatide | |
| 5. Bupropion / Naltrexone (Contrave) | For patients with craving-driven or emotional eating patterns | |
| Mechanism | Targets brain reward and appetite centers |
| FDA Status | Approved for chronic weight management |
| Key difference | Addresses behavioral drivers of overeating, not just metabolic factors |
| Average weight loss: 4-8% of body weightForm: oral tablet taken twice dailyHow it works: bupropion acts on dopamine and norepinephrine pathways; naltrexone blocks opioid receptors involved in food reward and craving cyclesBest for: patients whose weight gain is driven by emotional eating, cravings, or addictive food behaviors rather than purely metabolic factorsConsiderations: may increase blood pressure; not for patients with seizure disorders, those using opioid medications, or patients with active bulimia/anorexia | |
| 6. Metformin (off-label for weight loss) | Budget-friendly metabolic support for patients with elevated blood sugar | |
| Mechanism | Insulin sensitizer; reduces hepatic glucose output |
| FDA Status | Approved for T2D; off-label for weight loss |
| Best pairing | Often combined with GLP-1 therapy or lifestyle programs for additive benefit |
| Average weight loss: 2-5% of body weight (modest, but meaningful for some patients)Form: oral tablet taken once or twice daily with mealsHow it works: improves insulin sensitivity, reduces hepatic glucose production, and may modestly suppress appetiteBest for: patients with metabolic syndrome, prediabetes, or type 2 diabetes who need affordable, well-tolerated weight supportConsiderations: prescribed off-label for weight loss; not a substitute for GLP-1 therapy in patients with significant obesity. Most effective as part of a broader program.Cost: generic metformin is widely available for under $20/month | |
| 7. Medically Supervised Weight Loss Programs | The most sustainable long-term alternative for patients who need personalized care | |
| Approach | Multi-modal: medication + lifestyle + behavioral support |
| Supervision | Physician or NP-guided with regular check-ins |
| Availability | InjectCo: 9 Texas locations + virtual consultations statewide |
| What is included: physician or NP-guided program combining prescription medication, nutrition counseling, behavioral support, and regular monitoringAverage weight loss: variable, but higher adherence and sustainability than self-managed dietingBest for: anyone seeking a supervised, individualized approach, especially patients who have tried medications alone without long-term resultsAt InjectCo: our BriteBody medical weight loss program pairs GLP-1 medications with coaching and check-ins across 9 Texas locations including Fort Worth, Plano, Dallas, Austin, The Woodlands, Colleyville, Argyle, Cleburne, and WaxahachieBook a free 15-minute virtual consultation at injectco.com to discuss which medications and programs fit your goals | |
Use this table to compare your options side by side before your consultation.
| Alternative | Type | Avg. Weight Loss | Form | FDA Status | Best For |
| Semaglutide (Wegovy inject.) | GLP-1 RA | 10-15% | Weekly injection | Approved | Proven weekly GLP-1 for obesity |
| Oral Wegovy pill | GLP-1 RA (oral) | ~14-17% | Daily pill | Approved Dec 2025 | No-needle GLP-1 option |
| Liraglutide (Saxenda) | GLP-1 RA | 5-10% | Daily injection | Approved | Daily dosing preference |
| Phentermine/Topiramate | Appetite suppressant | 8-10% | Daily pill | Approved | Short-term, oral-only patients |
| Bupropion/Naltrexone | Craving control | 4-8% | Daily pill | Approved | Emotional/craving-driven eating |
| Metformin (off-label) | Insulin sensitizer | 2-5% | Daily pill | Off-label | Metabolic syndrome, budget patients |
| Retatrutide (GIP+GLP-1+glucagon) | Triple agonist | ~28% (Ph3 trials) | Weekly injection | NOT yet approved – Phase 3 | Future: patients needing max loss |
| Compounded GLP-1s | Custom peptide | Variable | Injectable | Not FDA-approved | Access/cost barriers to brand-name |
| Medical Weight Loss Programs | Multi-modal | Variable / sustained | Customized | N/A | Long-term, physician-supervised |
Cost is one of the biggest factors patients weigh when choosing a tirzepatide alternative. Here is a practical breakdown for Texas patients in 2026:
| Medication | Monthly Cost (self-pay) | With Insurance | Notes |
| Injectable Wegovy (semaglutide) | ~$349/mo (Novo Nordisk offer) | ~$25 co-pay eligible | Novo Nordisk savings program available |
| Oral Wegovy pill | From $149/mo (1.5 mg starting dose) | ~$25 co-pay eligible | At CVS, Costco, GoodRx, NovoCare Pharmacy |
| Compounded semaglutide (InjectCo) | Ask at consultation | N/A | Physician-supervised; pricing varies by dosage |
| Compounded tirzepatide (InjectCo) | Ask at consultation | N/A | Physician-supervised; pricing varies by dosage |
| Phentermine/Topiramate | ~$50-$150/mo | Often covered | Generic available; varies by pharmacy |
| Metformin | Under $20/mo | Typically covered | Lowest cost option; widely generic |
InjectCo pricing note: InjectCo offers competitive, transparent pricing for compounded semaglutide and tirzepatide in Texas. Book a free virtual consultation to get exact pricing for your dosage and program. We also accept CareCredit and Cherry financing for eligible patients.
The oral Wegovy pill launched in US pharmacies on January 5, 2026, marking the first time a GLP-1 receptor agonist for obesity has been available in pill form. It is now at over 70,000 US pharmacies, including CVS and Costco, and through telehealth providers like Ro and LifeMD.
Key facts for patients:
For Texas patients who want to explore whether the oral Wegovy pill or another GLP-1 option fits their lifestyle, InjectCo providers at our Fort Worth, Plano, Dallas, Austin, Colleyville, The Woodlands, Argyle, Cleburne, and Waxahachie locations can help you compare options and build a supervised plan.
There is no single best alternative for everyone. The right option depends on:
Always work with a qualified medical provider before starting or switching weight loss medications. At InjectCo, every patient starts with a consultation where our team reviews your health history and builds a plan that fits your goals, medical needs, and budget.
At InjectCo, we do not take a one-size-fits-all approach to weight loss. Our providers review your full health history, discuss your previous experiences with medications, and match you with the best available option, whether that is injectable semaglutide, compounded GLP-1 medications, our BriteBody program, or another treatment entirely.
We serve patients across Texas at nine locations:
Book your free 15-minute virtual consultation and let our team find the right plan for you.
Injectable semaglutide (Wegovy) is the closest alternative. Both are GLP-1 receptor agonists, both are given weekly, and semaglutide has the strongest clinical data of any currently approved single-pathway alternative. Tirzepatide adds a second hormone pathway (GIP) which accounts for its slightly greater average weight loss, but semaglutide still produces 10-15% body weight reduction for most patients.
Not yet. As of June 2026, there is no FDA-approved oral tirzepatide. Eli Lilly is researching oral formulations but none are commercially available. However, oral Wegovy (oral semaglutide 25 mg) launched in January 2026 and is the only FDA-approved oral GLP-1 for obesity. It is available now at major US pharmacies.
Retatrutide is a next-generation triple agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 TRIUMPH trials have shown average weight loss of up to 28.7%, the highest ever recorded in an obesity drug trial. However, retatrutide is NOT FDA-approved as of June 2026. An NDA submission is expected in late 2026 or Q1 2027, with potential approval in 2027-2028. Do not use compounded retatrutide without medical supervision.
Most are. Injectable semaglutide (Wegovy), oral semaglutide (Wegovy pill), liraglutide (Saxenda), phentermine/topiramate (Qsymia), and bupropion/naltrexone (Contrave) are all FDA-approved for obesity or chronic weight management. Metformin is FDA-approved for type 2 diabetes and used off-label for weight support. Compounded GLP-1 medications are not FDA-approved but can be legally prescribed by licensed providers. Retatrutide remains investigational.
Mounjaro and Zepbound both use tirzepatide, which activates both the GLP-1 and GIP receptors. Most alternatives, including semaglutide, only activate the GLP-1 receptor, which is why their average weight loss (10-15%) is slightly lower than tirzepatide’s (up to 26%). The oral Wegovy pill delivers similar GLP-1 receptor activity in pill form with ~14-17% average weight loss.
InjectCo offers compounded semaglutide, compounded tirzepatide, and our BriteBody medical weight loss program at nine Texas locations. We also connect patients with brand-name GLP-1 options and provide clinical guidance on oral alternatives. Book a free consultation to discuss what fits your goals.
Semaglutide (injectable or oral Wegovy): 10-17% | Phentermine/Topiramate: 8-10% | Bupropion/Naltrexone: 4-8% | Metformin: 2-5% | Retatrutide (not yet approved): ~28% in Phase 3 trials. Results depend on adherence, dosage, medical history, and lifestyle factors.
InjectCo has nine Texas locations and offers free virtual consultations for patients statewide. Our providers specialize in GLP-1 weight loss programs and can help you find the right medication or program whether you are new to treatment or looking to switch from a medication that stopped working for you.
days day
hours hour
minutes minute
seconds second
